Patents by Inventor Josef Straub
Josef Straub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11851492Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.Type: GrantFiled: March 14, 2022Date of Patent: December 26, 2023Assignee: Merck Patent GmbHInventors: Josef Straub, Eike Staub
-
Publication number: 20220334117Abstract: A new method can be used for treating colorectal cancer (CRC) and metastases thereof in subjects, and preferably also other solid cancers and metastases thereof in subjects. The method preferably depends on whether the patient shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment involves the administration of at least one pan ?v integrin inhibitor to a patient. A corresponding medicament is used in the new methods. A method can be used for predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the patient.Type: ApplicationFiled: June 17, 2022Publication date: October 20, 2022Inventors: Josef STRAUB, Eike Staub
-
Publication number: 20220275094Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.Type: ApplicationFiled: March 14, 2022Publication date: September 1, 2022Inventors: Josef STRAUB, Eike STAUB
-
Patent number: 11415581Abstract: The instant invention provides for a new method of treating colorectal cancer (CRC) and metastases thereof in subjects, and preferably also of other solid cancers and metastases thereof in subjects, wherein said method preferably depends on whether the patient shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a patient, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the patient.Type: GrantFiled: August 18, 2015Date of Patent: August 16, 2022Assignee: Merck Patent GmbHInventors: Josef Straub, Eike Staub
-
Patent number: 11306146Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.Type: GrantFiled: July 22, 2019Date of Patent: April 19, 2022Assignee: Merck Patent GmbHInventors: Josef Straub, Eike Staub
-
Publication number: 20200121788Abstract: Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.Type: ApplicationFiled: October 18, 2019Publication date: April 23, 2020Applicant: Merck Patent GmbHInventors: Giorgio MASSIMINI, Ilhan Celik, Josef Straub, Rolf Bruns
-
Publication number: 20190338037Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.Type: ApplicationFiled: July 22, 2019Publication date: November 7, 2019Inventors: JOSEF STRAUB, EIKE STAUB
-
Patent number: 10435472Abstract: The instant invention provides for a new method of treating bone metastasis diseases in subjects, wherein said method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the subject.Type: GrantFiled: August 18, 2015Date of Patent: October 8, 2019Assignee: Merck Patent GmbHInventors: Josef Straub, Eike Staub
-
Publication number: 20170298133Abstract: The instant invention provides for a new method of treating bone metastasis diseases in subjects, wherein said method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the subject.Type: ApplicationFiled: August 18, 2015Publication date: October 19, 2017Applicant: Merck Patent GmbHInventors: Josef STRAUB, Eike STAUB
-
Publication number: 20170298134Abstract: The instant invention provides for a new method of treating colorectal cancer (CRC) and metastases thereof in subjects, and preferably also of other solid cancers and metastases thereof in subjects, wherein said method preferably depends on whether the patient shows certain specific proteins levels in one or more body fluids prior to or during treatment, wherein said treatment comprises the administration of at least one pan ?v integrin inhibitor to a patient, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on said specific protein levels in one or more body fluids of the patient.Type: ApplicationFiled: August 18, 2015Publication date: October 19, 2017Applicant: Merck Patent GmbHInventors: Josef STRAUB, Elke STAUB
-
Publication number: 20170121775Abstract: Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used separately. Genes found to be epigenetically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ARTS-1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.Type: ApplicationFiled: February 9, 2016Publication date: May 4, 2017Applicants: MDxHealth, THE JOHNS HOPKINS UNIVERSITYInventors: Wim VAN CRIEKINGE, Josef STRAUB, Geert TROOSKENS, Stephen BAYLIN, James HERMAN, Kornel SCHUEBEL, Leslie COPE, Leander VAN NESTE
-
Publication number: 20120196827Abstract: Using a combination of analytic methods epigenetic silencing of markers in cancer have been determined. The cancers are generally those of the gastrointestinal tract including but not limited to esophageal, head and neck, gastric, pancreas, liver, and colon. The genes can be used for the early detection of cancer or can be used to identify adenomas that will likely progress to carcinomas. Therapeutic regimens based on the epigenetic silenced genes can be chosen and/or monitored. Kits for evaluating epigenetic silencing of these genes can be used for detection and monitoring.Type: ApplicationFiled: June 12, 2007Publication date: August 2, 2012Applicant: ONCOMETHYLOME SCIENCES S.A.Inventors: Wim Van Criekinge, Gerrit Meijer, Josef Straub, Beatriz Pinto Morais De Carvalho
-
Publication number: 20110117551Abstract: Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.Type: ApplicationFiled: February 19, 2009Publication date: May 19, 2011Applicants: ONCOMETHYLOME SCIENCES SA, THE JOHNS HOPKINS UNIVERSITYInventors: Wim Van Criekinge, Josef Straub, Geert Trooskens, Stephen Baylin, James Herman, Kornel Schuebel, Leslie Cope, Leander Van Neste
-
Publication number: 20100035970Abstract: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: April 17, 2006Publication date: February 11, 2010Applicants: Oncomethylome Sciences, S.A., The Johns Hopkins UniversityInventors: Wim Van Criekinge, Josef Straub, David Sidransky
-
Publication number: 20090215709Abstract: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: October 13, 2006Publication date: August 27, 2009Applicants: Johns Hopkins University, OncoMethylome Sciences, S.A.Inventors: Wim Van Criekinge, Josef Straub, David Sidransky
-
Publication number: 20090203639Abstract: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: April 17, 2006Publication date: August 13, 2009Applicant: Oncomethylome Sciences, Inc.Inventors: Wim Van Criekinge, Josef Straub, Bea Wisman
-
Patent number: 7507536Abstract: Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: GrantFiled: October 6, 2006Date of Patent: March 24, 2009Assignees: The Johns Hopkins University, OncoMethylome Sciences, S.A.Inventors: Wim Van Criekinge, Josef Straub, Nathalie Sieben
-
Publication number: 20090011049Abstract: Genes for thirteen DNA damage repair or DNA damage response enzymes can be epigenetically silenced in cancers. The silencing of nucleic acids encoding a DNA repair or DNA damage response enzyme can be used prognostically and for selecting treatments that are well tailored for an individual patient. Combinations of these markers can also be used to provide prognostic information. Kits for testing epigenetic silencing can be used to determine a prognosis or a therapeutic regimen.Type: ApplicationFiled: July 28, 2006Publication date: January 8, 2009Applicant: ONCOMETHYLOME SCIENCESInventors: Wim Wim Van Criekinge, Josef Straub
-
Publication number: 20070087365Abstract: Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: October 6, 2006Publication date: April 19, 2007Inventors: Wim Van Criekinge, Josef Straub, Nathalie Sieben